IGC Pharma announces the expansion of the #calma #Phase2 #clinicaltrials to Hamilton Health Sciences in #canada. This expansion strengthens research efforts into IGC-AD1, an investigational #cannabinoidbased #therapy for #agitation in #alzheimers #dementia. With trial sites now active across the #usa and Canada, IGC Pharma is accelerating #patientenrollment to advance IGC-AD1 toward #Commercialization. For more details on the CALMA trial, visit: • clinicaltrials.gov/study/NCT…... For updates on IGC-AD1 and other developments, visit: • igcpharma.com/igc-ad1-phase-… #igcpharma #alzheimersresearch #clinicaltrials #neurodegeneration

We’ve secured our #HealthCanada Research #Licence at our #Toronto HQ! $AVCN is the only cannabinoid company in Discovery District permitted to work with #cannabinoidbased #formulations & #pharma drug deliveries. #AvicannaAdvantage #ScienceFirst bit.ly/2z7u3h9

Dr. Frantz Le Devedec is one of our experts in formulation & product development. He leads the design of our drug development programs focusing on safety, stability, enhanced #bioavailability & targeted delivery of our #cannabinoidbased solutions #ScienceFirst #CDNbiotech #CDNSci

PharmaCyte Biotech Research Identifies Enzyme Activity for CannabinoidBased Therapy to Fight Cancer ow.ly/z3Um50eEFeO